|
|
 |
|
Viewing report
|
|
|
|
Epidemiology: Peripheral Neuropathic Pain - A common co-morbidity for HIV, diabetes, and herpes zoster
Datamonitor, Oct 2011, Pages: 73
The prevalence of neuropathic pain is estimated at approximately 10% in the adult population of the US, and is likely to be the same in other developed countries. Peripheral neuropathic pain is a common co-morbidity in HIV, diabetes, and herpes zoster; it affects approximately 22% of HIV-positive individuals, 6% of type 1 diabetics, 18% of type 2 diabetics, and 6–18% of herpes zoster cases.
Features and benefits
- Gain insight into market potential, including a robust 10-year epidemiology forecast of neuropathic pain cases in HIV, diabetes, and herpes zoster.
- Understand the key epidemiologic risk factors associated with peripheral neuropathic pain in HIV, diabetes, and herpes zoster.
Highlights
- During 2010, Datamonitor estimates that 239,700 diagnosed, prevalent HIV cases with peripheral neuropathic pain existed in the seven major markets (the US, Japan, France, Germany, Italy, Spain, and the UK). Between 2010 and 2020, Datamonitor forecasts these cases to increase by 17% in the seven major markets, resulting in 279,900 cases in 2020.
- Among the diagnosed diabetic population in 2010, Datamonitor estimates that 128,500 and 5.59 million prevalent types 1 and 2 diabetes cases with diabetic peripheral neuropathic pain (DPNP), respectively, existed in the seven major markets. Between 2010 and 2020, Datamonitor forecasts both diabetes types 1 and 2 DPNP cases to increase by 14%.
- During 2010, Datamonitor estimates that 249,000 diagnosed, incident post-herpetic neuralgia cases existed in the seven major markets. Between 2010 and 2020, Datamonitor forecasts these cases to increase by 16% in the seven major markets, resulting in 288,000 cases in 2020.
Your key questions answered
- What are the most robust sources for prevalence or incidence data on peripheral neuropathic pain in HIV, diabetes, and herpes zoster?
- How will the patient population change over the next decade in the US, Japan, and five major EU markets (France, Germany, Italy, Spain, and the UK)?
- How do changes in population structure and risk factors affect the trends in HIV, diabetes, and herpes zoster peripheral neuropathic pain cases?
|
|
|
|
